Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079339 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL5208692 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311909 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL16933147 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL27420754 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL15215618 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL17732171 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL5828798 | 0.98 | MGLL (0.68) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL18157046 | 0.90 | PTGS1 (0.62) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL10126653 | 0.90 | MGLL (0.67) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2024-11-26 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | MGLL 1137/4885PTGS1 3119/4885PTGS2 2902/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | MGLL 3169/4885PTGS1 2591/4885PTGS2 3499/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | MGLL 4667/4885PTGS1 3702/4885PTGS2 4529/4885 |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | MGLL 3221/4885PTGS1 4300/4885PTGS2 4827/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | MGLL 4551/4885PTGS1 4626/4885PTGS2 4674/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | MGLL 4667/4885PTGS1 3702/4885PTGS2 4529/4885 |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | MGLL 2504/4885PTGS1 4562/4885PTGS2 4610/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | MGLL 4646/4885PTGS1 4814/4885PTGS2 4857/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | MGLL 3175/4885PTGS1 4442/4885PTGS2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.